In this episode of Talk Radioisotopes, host Scott Larrivee and guest Paul Schrimpf, Proprietor and Entrepreneur at Cyrall, unpacks what it takes to build and scale a radiopharmaceutical business.
With a background spanning Accenture, Prophet, and leadership roles advising top healthcare organizations, Paul draws on deep experience across strategy, marketing, and team development to lay out what radiopharma innovators can learn from the broader B2B and life sciences sectors. He explains why too many startups fall in love with their technology before identifying a buyer, and why clarity, not complexity, is the foundation of effective communication.
Paul also explores how AI is reshaping early-stage strategy—not by replacing decision-makers, but by accelerating hypothesis development, sharpening messaging, and driving customer-centric thinking. He shares practical frameworks for using tools like ChatGPT to refine go-to-market models, stress-test assumptions, and identify real buyers, not just theoretical markets.
The conversation then pivots to commercialization strategy, where Paul critiques outdated pharma marketing playbooks and highlights the untapped potential of personalization and digital targeting. He also challenges old-school sales mentalities, urging founders and go-to-market teams to prioritize listening over pitching. Whether you’re building a radiopharma company or advising one, this episode is packed with tactical insights into what it takes to succeed in today’s healthcare environment.
——–
Time Stamps:
- *(4:45) Business Comes Down to People
- *(8:15) Addressing Unmet Needs and the Biggest Mistakes Startups Make
- *(21:20) What Pharma Marketing Still Gets Wrong
- *(24:50) Where is the Consumer?
- *(32:00) What Space is Radiopharma in the Future?
——–
‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.
——–
Links:
